These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17361914)

  • 41. Prostate-specific antigen density.
    Beduschi MC; Oesterling JE
    Urol Clin North Am; 1997 May; 24(2):323-32. PubMed ID: 9126230
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Prostate carcinoma: prostate-specific antigen--and then what?].
    Schmid HP
    Ther Umsch; 1998 Jul; 55(7):426-8. PubMed ID: 9702110
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transperineal template-guided prostate biopsy for patients with persistently elevated PSA and multiple prior negative biopsies.
    Gershman B; Zietman AL; Feldman AS; McDougal WS
    Urol Oncol; 2013 Oct; 31(7):1093-7. PubMed ID: 22305626
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A medical reveals a slightly raised PSA.
    Spira M; Kirby M; Williams G
    Practitioner; 1997 Jun; 241(1575):303, 307-10, 313 passim. PubMed ID: 9230511
    [No Abstract]   [Full Text] [Related]  

  • 45. PSA implications and medical management of prostate cancer for the primary care physician.
    Rehsia S; Shayegan B
    Can J Urol; 2012 Oct; 19 Suppl 1():28-35. PubMed ID: 23089345
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnosis of localized prostate cancer: 10 years of progress.
    Feneley MR; Partin AW
    Curr Opin Urol; 2000 Jul; 10(4):319-27. PubMed ID: 10918970
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prostate biopsy: who, how and when. An update.
    Djavan B; Milani S; Remzi M
    Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
    Bretton PR; Evans WP; Borden JD; Castellanos RD
    Cancer; 1994 Dec; 74(11):2991-5. PubMed ID: 7525040
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The prognostic value of transrectal ultrasound guided biopsy in patients over 70 years old with a prostate specific Antigen (PSA) level ≤ 15 ng/ml and normal digital rectal examination: a 10-year prospective follow-up study of 427 consecutive patients.
    Mohamed ZK; Dominguez-Escrig J; Vasdev N; Bharathan B; Greene D
    Urol Oncol; 2013 Nov; 31(8):1489-96. PubMed ID: 22591749
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How to use PSA to screen for prostate cancer.
    Little B; Young M
    Int J Clin Pract; 2003; 57(1):40-2. PubMed ID: 12587941
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
    Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
    BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patients' preferences for communicating a prostate cancer diagnosis and participating in medical decision-making.
    Davison BJ; Parker PA; Goldenberg SL
    BJU Int; 2004 Jan; 93(1):47-51. PubMed ID: 14678366
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparative study of prostate cancer detection and management in China and in France.
    Peyromaure EM; Mao K; Sun Y; Xia S; Jiang N; Zhang S; Wang G; Liu Z; Debré B
    Can J Urol; 2009 Feb; 16(1):4472-7. PubMed ID: 19222885
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Second opinions from urologists for prostate cancer: Who gets them, why, and their link to treatment.
    Radhakrishnan A; Grande D; Mitra N; Bekelman J; Stillson C; Pollack CE
    Cancer; 2017 May; 123(6):1027-1034. PubMed ID: 28263389
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostate-specific antigen: questions often asked.
    Killian CS; Chu TM
    Cancer Invest; 1990; 8(1):27-37. PubMed ID: 1693541
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff.
    Luboldt HJ; Bex A; Swoboda A; Hüsing J; Rübben H;
    Eur Urol; 2001 Feb; 39(2):131-7. PubMed ID: 11223671
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
    Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
    BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation of prostate-specific antigen and prostate-specific antigen density with outcome of prostate biopsy.
    Bare R; Hart L; McCullough DL
    Urology; 1994 Feb; 43(2):191-6. PubMed ID: 7509526
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.